Business Wire

ISAE-SUPAERO's "Collaborative Rover and Drone" Project, Facilitating the Exploration of the Moon

21.6.2021 10:54:00 EEST | Business Wire | Press release

Share

While Thomas Pesquet launched on April 22 as part of the Alpha mission, one of humanity's biggest challenges remains even further away than the ISS, 400,000 km from Earth: the establishment of a lunar base. But before being able to settle on the Moon in a prolonged way to exploit its resources or as a logistic support for future exploration missions further away, an exploration work is necessary. The use of autonomous robotic systems would allow mapping of dangerous or hard-to-reach areas from space, before eventually deploying infrastructure such as a spaceport or human habitation.

Faced with this exploration challenge, the Space Advanced Concepts Laboratory (SaCLaB) of ISAE-SUPAERO in Toulouse and a team of students from the Institute are developing the Collaborative Rover and Drone (CoRoDro) project to study navigation and autonomous operations for space robotic systems. This scientific study is one of 12 university technology projects selected in 8 different countries as part of the IGLUNA* 2021 initiative supported by the European Space Agency (ESA)

The concept of CoRoDro is to develop the interaction of a drone and a rover. In concrete terms, the drone locates and maps its environment, which it transmits to the rover so that the latter can analyze it and choose the most relevant points to move around and conduct scientific experiments. Thanks to the cartography made by the drone, the rover is able to choose the shortest path and to determine the possible obstacles, which allows to shorten each exploration mission.

The objective of this project is to see up to what point it is possible to trust the work of robots to move and make decisions in total autonomy, and to determine what level of decision making is attributed to the human to react in particular to unforeseen events. In the perspective of a lunar installation, the robots would intervene in support of critical activities.

The CoRoDro project allows to gain knowledge and to test in real size multiple theories concerning the servitude of the future space station, the exploitation of the resources of the Moon, or the analysis of the collaboration between the crew and the robots for the critical and dangerous activities

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Leïla Colaud
leila.c@oxygen-rp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release

Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen

AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release

Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer

Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release

Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release

CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye